Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort

Figures & data

Table 1. Descriptive characteristics of the study participants (N:86).

		Mean (range)
Age (years)		38(20–45)
		N(%)
^aBMI (Kg/m2)	<26	40(46.5)
	≥26	46(53.5)
^bIMS	Luminal A	13(15.1)
	Luminal B	39(45.3)
	HER2 positive	19(22.0)
	Triple negative	15(17.4)
T Stage	T1-2	28(32.6)
	T3-4	58(67.4)
N Stage	N0-1	48(55.8)
	N2-3	38(44.2)
Neoadjvant CT	^cAnthra. and/or tax.	79(91.9)
Sugery	^dBCS	42(48.8)
	Mastectomy	44(51.2)
Adjuvant CT	Anthra. and/or tax
^eRT	Yes	56(65.1)
^fHT	Yes	54(62.8)

^a BMI: Body mass index. BMI categories were defined upon the mean value computed for this study population, i.e., 26

^b IMS (Intrinsic Molecular Subtype): Clinico-pathologic surrogate definition of intrinsic subtypes of breast cancer (26 in the reference list)

^c Neoadjuvant CT: Anthra. and/or tax.: Anthracycline-and/or Taxane-based regimen

^d BCS: Breast Conservative Surgery

^e RT: Adjuvant radiotherapy

^f HT: Adjuvant hormone therapy.

Table 2. Pathologic complete response(pCR) in the overall study population and in subgroups defined by participant- and disease-related features (N:19 pCR out of 86 study participants).

			N(%)	p
pCR			19(22.1)
	Age	<38	9 (47.4)	.52
		≥38	10 (52.6)
	^aBMI	<26	12(63.2)	0.05
		≥26	7(36.8)
	^bIntrinsic Molecular Subtypes	Luminal ALuminal BHER2 positiveTriple negative	2(10.5)9(47.4)3(15.8)5(26.3)	.593
	T Stage N Stage	1-23-40-12-3	7(36.8)12(63.2)10(52.6)9(47.4)	.424.430
	Neoadj. CT	^cAnt.and/orTax.	12(63.2)	.200
		Other	7(36.8)

^a BMI: Body mass index (Kg/m2), BMI categories were defined upon the mean value computed for this study population, i.e., 26

^b IMS (Intrinsic Molecular Subtype): Clinico-pathologic surrogate definition of intrinsic subtypes of breast cancer (Reference 26)

^c Neoadjuvant CT: Anthra. and/or tax.: Anthracycline-and/or Taxane-based regimens.

Figure 1. Overall survival (OS) by subgroups defined upon BMI, i.e., BMI: <26 and BMI≥26.

Figure 2. Overall survival (OS) by subgroups defined upon intrinsic molecular subtype (IMS).

Figure 3. Overall survival (OS) by subgroups defined upon adjuvant radiotherapy (RT).

Table 3. Cox proportional hazards models of factors associated with Overall Survival (N:86).

	Hazard Ratios	95%CI^a	p
BMI^2	0.30	0.12-0.71	0.007
IMS^3			0.008
I	0.43	0.15-1.21	0.011
II	0.04	0.01-0.35	0.003
III	0.30	0.12-0.75	0.010
T Stage	0.58	0.23-1.46	0.247
RT^4	2.41	1.12-5.18	0.024

¹ 95%CI: 95% Confidence Interval

² BMI: Body mass index

³ IMS: Intrinsic molecular subtype: the reference category is the triple negative (TN) subtype (reference: 26)

⁴ RT: radiotherapy.